NasdaqCM - Nasdaq Real Time Price USD

NeuroMetrix, Inc. (NURO)

4.5800

0.0000

(0.00%)

At close: May 1 at 4:00:00 PM EDT

electroCore completes acquisition of neurotechnology solution provider NeuroMetrix

NeuroMetrix’s Quell platform is a cloud-enabled wearable neuromodulation solution intended to treat fibromyalgia symptoms.

Medical Device Network 9 days ago

ECOR

NURO
0.00%
Here’s Why NeuroMetrix, Inc. (NASDAQ:NURO) Is Among the Best Diabetes Stocks to Buy Under $10

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where NeuroMetrix, Inc. (NASDAQ:NURO) stands against the other diabetes stocks. Global Growth and Innovation in Diabetes Care: The Rise of Continuous Glucose Monitors and AI Integration About 422 million people […]

Insider Monkey 4 months ago

NURO
0.00%
NeuroMetrix to be Acquired by electroCore

NeuroMetrix shareholders to receive cash and Contingent Value RightsWOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, will acquire NeuroMetrix. The transaction has been unanimously approved by the Boards of Directors of both companies and is expec

GlobeNewswire 4 months ago

NURO
0.00%

ECOR
NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth

Despite a 51% revenue dip, NURO narrowed losses in Q3 2024 by reducing operating expenses by 25%, offsetting the challenging revenue environment.

Zacks 6 months ago

NURO
0.00%
NeuroMetrix Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023)

NeuroMetrix ( NASDAQ:NURO ) Third Quarter 2024 Results Key Financial Results Revenue: US$587.3k (down 51% from 3Q...

Simply Wall St. 6 months ago

NURO
0.00%
NeuroMetrix Reports Q3 2024 Business Highlights

Company Continues to Pursue Review of Strategic AlternativesWOBURN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine months ended September 30, 2024. The Company develops proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. NeuroMetrix, Inc. is actively pursuing its previously announced review of strategic options to enhance shareholder value.

GlobeNewswire 6 months ago

NURO
0.00%
NeuroMetrix Reiterates its Review of Strategic Alternatives

WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past 6 months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, oper

GlobeNewswire 8 months ago

NURO
0.00%
NeuroMetrix Second Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023)

NeuroMetrix ( NASDAQ:NURO ) Second Quarter 2024 Results Key Financial Results Revenue: US$769.1k (down 54% from 2Q...

Simply Wall St. 8 months ago

NURO
0.00%
NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options

WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, t

GlobeNewswire 9 months ago

NURO
0.00%
NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024. For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and uniqu

GlobeNewswire 9 months ago

NURO
0.00%
NeuroMetrix Reports Q1 2024 Business Highlights

WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. “We are focused on maximizing shareholder value,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. “Shareholders have recently provided valuable insights in addition t

GlobeNewswire 11 months ago

NURO
0.00%

Performance Overview

Return	NURO	DAX P (^GDAXI)
YTD	+15.66%	+18.18%
1-Year	+0.88%	+25.71%
3-Year	-81.83%	+67.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NeuroMetrix, Inc. (NURO)

electroCore completes acquisition of neurotechnology solution provider NeuroMetrix

Here’s Why NeuroMetrix, Inc. (NASDAQ:NURO) Is Among the Best Diabetes Stocks to Buy Under $10

NeuroMetrix to be Acquired by electroCore

NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth

NeuroMetrix Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023)

NeuroMetrix Reports Q3 2024 Business Highlights

NeuroMetrix Reiterates its Review of Strategic Alternatives

NeuroMetrix Second Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023)

NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options

NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

NeuroMetrix Reports Q1 2024 Business Highlights

Performance Overview